Document:

EXHIBIT
10.36.3 

 

AMENDED
NOTE EXTENSION AGREEMENT

 

This
Amended Note Extension Agreement (“Amended Extension Agreement”), is made and entered into this 30th day
of May 2019, effective as of January 30, 2019 (the “Effective Date”), by and among Accelerated Pharma, Inc., a Delaware
corporation (the “Company”), and the parties (each a “Note Holder” and collectively, the “Note Holders”)
identified on the Note Holder Conversion Schedule attached hereto. The Company and the Note Holders are sometimes referred to
individually, as a “Party” and collectively, as the “Parties.”

 

WHEREAS,
the Company and Note Holders identified on Schedule A hereto entered into Securities Purchase Agreements (collectively, the “Securities
Purchase Agreements” or “SPAs”) and other transaction documents (collectively, “Transaction Documents”)
dated as of December 23, 2014, May 8, 2015, June 11, 2015, November 6, 2015, April 20, 2016, April 22, 2016, May 9, 2016, May
27, 2016, July 15, 2016 and the unsigned September 2017 SPA (the April 20, 2016, April 22, 2016, May 9, 2016, May 27, 2016, July
15, 2016 and the unsigned September 2017 SPA, and several other Securities Purchase Agreements with dates ranging between July
2016 through September 2017; and

 

WHEREAS,
pursuant to the Transaction Documents, the Company issued to the Note Holders certain secured convertible notes having maturity
date of December 31, 2017 (“2014-2016 Notes”); and

 

WHEREAS,
in 2017, the Note Holders exchanged warrants previously issued by the Company for 1,104,740 shares of the Company’s common
stock, par value $0.00001 (the “Common Stock”), all of which shares are
eligible for resale by the Note Holders pursuant to the provisions of Rule 144, promulgated by the United States Securities and
Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Act”); and

 

WHEREAS,
in October 2018, the Parties, understanding that the Company was in the process of filing a registration statement on Form S-1
(the “Registration Statement”) with the SEC for its initial public offering (“IPO”), agreed to a Note
Extension Agreement in contemplation of the IPO; and

 

WHEREAS,
on October 22, 2018, the Company filed the Registration Statement for the issuance and sale of 750,000 units (the “Units”)
at a price of $4.00 per Unit, each consisting of one (1) share of common stock, par value $0.00001 (the “Common Stock”)
and one (1) Class A Warrant exercisable for a period of five (5) years to purchase one (1) additional share of Common Stock at
an exercise price of $4.40 per share, and filed the Form of Note Extension Agreement as Exhibit 10.36 to the Registration Statement
which provided for the extension of the maturity date on the Notes to January 31, 2019; and

 

    	 	 	 

    	 

    

 

WHEREAS,
the Parties acknowledge that the Notes may be deemed to be past due and in connection with the completion of the audit of the
Company’s consolidated financial statements for the year-ended December 31, 2017 (the “2017 Financial Statements”)
and the filing of the Registration Statement, Registration Statement No. 333- 22791, which was filed with the SEC on October 22,
2018, and the amended Registration Statement was filed with the SEC on January 25, 2019, the Company has requested and the Note
Holders have agreed to: (i) further extend the maturity dates of the Notes from January 31, 2019 to December 31, 2019 (the
“New Maturity Date”), with the understanding that the New Maturity Date may be extended pursuant to a separate written
agreement between the Parties; (ii) waive any Events of Default (as that term is defined in the Transaction Documents) that occurred
or may have occurred prior to the date hereof; and (iii) the Note Holders have agreed that for good and valuable consideration,
upon the effective date of the pending Registration Statement, when and if declared by the SEC under the Act, to convert their
Notes and all accrued interest, with respect to certain Note Holders into shares of Common Stock at a conversion price of $1.60
and with respect to certain other Note Holders, all as set forth in Schedule A, into shares of the Company’s Series C Convertible
Preferred Stock as as set forth in Schedule A hereto.

 

NOW,
THEREFORE, the Company and Note Holders hereby agree as follows:

 

1.
The New Maturity Date of the 2014 Notes and the 2015 Notes is extended to December 31, 2019, effective as of January
30, 2019 (the “Effective Date”).

 

2.
As of the Effective Date and only in connection with this Amended Extension Agreement, the undersigned Note Holders agree to:
(i) waive any Events of Default that have occurred or may have occurred prior to the date hereof; (ii) waive any restrictions
contained in the Transaction Documents in order to afford the Company the opportunity to successfully implement and complete the
IPO; and (iii) the adoption of the New Maturity Date.

 

3.
The undersigned Note Holders each represent to the Company that he/she/it is the holder of the Notes in the amounts set forth
on Schedule A hereto, he/she/it has not sold, transferred or otherwise assigned any of the Notes and he/she/it has the authority
to enter into and deliver this Amended Extension Agreement.

 

4.
This Amended Extension Agreement may be executed in counterparts, each of which shall be deemed an original but all of which shall
together constitute one and the same instrument. This Extension Agreement may be signed and delivered by facsimile or electronically
and such facsimile or electronically signed and delivered Extension Agreement shall be enforceable.

 

IN
WITNESS WHEREOF, the Company and the undersigned Note Holders have caused this Amended Extension Agreement to be executed as of
the date first written above.

 

	 	ACCELERATED
    PHARMA, INC.
	 	Agreed
    to and Accepted by: 
	 	 
	 	/s/:
    Michael Fonstein
	 	Name:	Michael
    Fonstein
	 	Title:	Chief
    Executive Officer

 

    	 	 	 

    	 

    

 

	Note Holder	 	Principal Amount	 	 	Accrued Interest	 	 	Total Amount Oustanding	 	 	Date of Issuance	 	 	Securities Issuable on Conversion	 	Number of Shares	 
	HSI Partnership	 	$	50,000.00	 	 	$	17,888.89	 	 	$	67,888.89	 	 	12/29/14	 	 	Common Stock	 	 	42,431	 
	Nachum Stein	 	$	100,000.00	 	 	$	35,777.78	 	 	$	135,777.78	 	 	12/29/14	 	 	Common Stock	 	 	84,861	 
	American European Insurance Co.	 	$	100,000.00	 	 	$	35,777.78	 	 	$	135,777.78	 	 	12/29/14	 	 	Common Stock	 	 	84,861	 
	RR Investment 2012 LP	 	$	50,000.00	 	 	$	17,888.89	 	 	$	67,888.89	 	 	12/29/14	 	 	Common Stock	 	 	42,431	 
	Morris Fuchs	 	$	50,000.00	 	 	$	17,888.89	 	 	$	67,888.89	 	 	12/29/14	 	 	Common Stock	 	 	42,431	 
	Curber International LTD.	 	$	400,000.00	 	 	$	143,111.11	 	 	$	543,111.11	 	 	12/23/14	 	 	Common Stock	 	 	339,444	 
	RR Investment 2012 LP	 	$	500,000.00	 	 	$	144,861.11	 	 	$	644,861.11	 	 	5/8/15	 	 	Common Stock	 	 	403,038	 
	2004 Leon Scharf Irrevocable Trust Corp.	 	$	100,000.00	 	 	$	28,972.22	 	 	$	128,972.22	 	 	5/8/15	 	 	Common Stock	 	 	80,608	 
	Abraham Belsky	 	$	50,000.00	 	 	$	14,486.11	 	 	$	64,486.11	 	 	5/8/15	 	 	Common Stock	 	 	40,304	 
	Alpha Capital	 	$	750,000.00	 	 	$	217,291.67	 	 	$	967,291.67	 	 	5/8/15	 	 	Series C Convertible
    Preferred1	 	 	1,209	 
	API Bio Investors	 	$	340,000.00	 	 	$	98,505.56	 	 	$	438,505.56	 	 	5/8/15	 	 	Common Stock	 	 	274,066	 
	Brio Capital	 	$	110,000.00	 	 	$	31,869.44	 	 	$	141,869.44	 	 	5/8/15	 	 	Series C Convertible
    Preferred1	 	 	177	 
	Edwin W. Colman Children’s Trust	 	$	100,000.00	 	 	$	28,972.22	 	 	$	128,972.22	 	 	5/8/15	 	 	Common Stock	 	 	80,608	 
	Eli Inzlicht-Sprei	 	$	25,000.00	 	 	$	7,243.06	 	 	$	32,243.06	 	 	5/8/15	 	 	Common Stock	 	 	20,152	 
	Harvey Lang	 	$	25,000.00	 	 	$	7,243.06	 	 	$	32,243.06	 	 	5/8/15	 	 	Common Stock	 	 	20,152	 
	Hoch Family Equities, LLC	 	$	50,000.00	 	 	$	14,486.11	 	 	$	64,486.11	 	 	5/8/15	 	 	Common Stock	 	 	40,304	 
	Bernard Lazarus	 	$	50,000.00	 	 	$	14,486.11	 	 	$	64,486.11	 	 	6/11/15	 	 	Common Stock	 	 	40,304	 
	API Bio Investors	 	$	220,000.00	 	 	$	57,193.89	 	 	$	277,193.89	 	 	11/6/15	 	 	Common Stock	 	 	173,246	 
	Mordechai Marc Belsky	 	$	50,000.00	 	 	$	12,998.61	 	 	$	62,998.61	 	 	11/6/15	 	 	Common Stock	 	 	39,374	 
	Keren Brocha	 	$	35,000.00	 	 	$	9,099.03	 	 	$	44,099.03	 	 	11/6/15	 	 	Common Stock	 	 	27,562	 
	Chaim Gross	 	$	30,000.00	 	 	$	7,799.17	 	 	$	37,799.17	 	 	11/6/15	 	 	Common Stock	 	 	23,624	 
	Hoch Family Equities, LLC	 	$	100,000.00	 	 	$	25,997.22	 	 	$	125,997.22	 	 	11/6/15	 	 	Common Stock	 	 	78,748	 
	Morris Fuchs	 	$	50,000.00	 	 	$	12,998.61	 	 	$	62,998.61	 	 	11/6/15	 	 	Common Stock	 	 	39,374	 
	Eli Inzlicht-Sprei	 	$	15,000.00	 	 	$	3,899.58	 	 	$	18,899.58	 	 	11/6/15	 	 	Common Stock	 	 	11,812	 
	Leon Scharf	 	$	100,000.00	 	 	$	22,458.33	 	 	$	122,458.33	 	 	4/20/16	 	 	Common Stock	 	 	76,536	 
	Venture Cap Group	 	$	50,000.00	 	 	$	11,229.17	 	 	$	61,229.17	 	 	4/20/16	 	 	Common Stock	 	 	38,268	 
	HSI Partnership	 	$	20,000.00	 	 	$	4,491.67	 	 	$	24,491.67	 	 	4/22/16	 	 	Common Stock	 	 	15,307	 
	Nachum Stein	 	$	40,000.00	 	 	$	8,983.33	 	 	$	48,983.33	 	 	4/22/16	 	 	Common Stock	 	 	30,615	 
	American European	 	$	40,000.00	 	 	$	8,983.33	 	 	$	48,983.33	 	 	4/22/16	 	 	Common Stock	 	 	30,615	 
	Manuel Scharf	 	$	100,000.00	 	 	$	21,855.56	 	 	$	121,855.56	 	 	5/9/16	 	 	Common Stock	 	 	76,160	 
	Shein Ventures	 	$	100,000.00	 	 	$	21,855.56	 	 	$	121,855.56	 	 	5/27/16	 	 	Common Stock	 	 	76,160	 
	Yuri Rabinovich	 	$	50,000.00	 	 	$	10,636.11	 	 	$	60,636.11	 	 	6/21/16	 	 	Common Stock	 	 	37,898	 
	Masoud Togrhraie	 	$	150,000.00	 	 	$	31,908.33	 	 	$	181,908.33	 	 	7/1/16	 	 	Common Stock	 	 	113,693	 
	Ross Overbeek	 	$	20,000.00	 	 	$	4,133.89	 	 	$	24,133.89	 	 	7/12/16	 	 	Common Stock	 	 	15,084	 
	Alpha Capital	 	$	50,000.00	 	 	$	10,334.72	 	 	$	60,334.72	 	 	7/15/16	 	 	Series C Convertible
    Preferred1	 	 	75	 
	Raymond Dayan	 	$	40,000.00	 	 	$	8,267.78	 	 	$	48,267.78	 	 	7/15/16	 	 	Common Stock	 	 	30,167	 
	Brio Capital	 	$	25,000.00	 	 	$	5,167.36	 	 	$	30,167.36	 	 	7/15/16	 	 	Series C Convertible
    Preferred1	 	 	38	 
	Masoud Togrhraie	 	$	50,000.00	 	 	$	10,636.11	 	 	$	60,636.11	 	 	7/1/16	 	 	Common Stock	 	 	37,898	 
	Edwin w. Colman Children’s Trust	 	$	50,000.00	 	 	$	10,033.33	 	 	$	60,033.33	 	 	8/5/16	 	 	Common Stock	 	 	37,521	 
	2004 Loen Scharf Irrevocable Trust	 	$	50,000.00	 	 	$	10,033.33	 	 	$	60,033.33	 	 	8/5/16	 	 	Common Stock	 	 	37,521	 
	Michael Schwartz	 	$	120,000.00	 	 	$	24,080.00	 	 	$	144,080.00	 	 	8/29/16	 	 	Common Stock	 	 	90,050	 
	Walter Schenker IRA #1374	 	$	50,000.00	 	 	$	9,741.67	 	 	$	59,741.67	 	 	9/22/16	 	 	Common Stock	 	 	37,339	 
	Sturling Advisors LLP	 	$	105,000.00	 	 	$	20,457.50	 	 	$	125,457.50	 	 	9/26/16	 	 	Common Stock	 	 	78,411	 
	Asher Hartman	 	$	26,000.00	 	 	$	5,065.67	 	 	$	31,065.67	 	 	9/27/16	 	 	Common Stock	 	 	19,416	 
	Scott Greenberg	 	$	50,000.00	 	 	$	9,741.67	 	 	$	59,741.67	 	 	9/30/16	 	 	Common Stock	 	 	37,339	 
	DNR	 	$	50,000.00	 	 	$	9,693.06	 	 	$	59,693.06	 	 	10/6/16	 	 	Common Stock	 	 	37,308	 
	AJH	 	$	50,000.00	 	 	$	9,693.06	 	 	$	59,693.06	 	 	10/6/16	 	 	Common Stock	 	 	37,308	 
	Alpha Capital	 	$	75,000.00	 	 	$	8,808.33	 	 	$	83,808.33	 	 	11/3/17	 	 	Series C Convertible
    Preferred1	 	 	105	 
	Brio Capital	 	$	25,000.00	 	 	$	2,936.11	 	 	$	27,936.11	 	 	11/3/17	 	 	Series C Convertible
    Preferred1	 	 	35	 
	Chaim Gross	 	$	100,000.00	 	 	$	11,686.11	 	 	$	111,686.11	 	 	11/6/17	 	 	Common Stock	 	 	69,804	 

 

 

1
Each share of Series C Convertible Preferred Stock is convertible into 500 shares of Common Stock, subject to a Beneficial
Ownership Limitation set forth in the Certificate of Designation-Series C Convertible Preferred Stock.EXHIBIT
10.37.3 

 

 AMENDED
 PRIVATE SECURITIES PURCHASE AND ASSIGNMENT AGREEMENT

 

This
PRIVATE SECURITIES PURCHASE AND ASSIGNMENT AGREEMENT (the “Agreement”), dated as of January 17, 2019, is by
and between Alpha Capital Anstalt (“Alpha”), organized under the laws of Liechtenstein, with offices located at Lettstrasse
32, 9490 Vaduz, Liechtenstein and Brio Capital Master Fund Ltd (“Brio”), organized under the laws of the Cayman Islands
with offices located at 100 Merrick Road, Suite 401, W. Rockville Center, NY 11570 (each of Alpha and Brio may be referred to
collectively, as the “Purchasers” and individually, as a “Purchaser”), on the one hand, and Firstfire
Global Opportunities Fund, LLC (“Firstfire”), a New York limited liability company, with offices at 1040
First Avenue, Suite 190, New York, NY 10022 and Efrat Investments LLC, a Delaware limited liability company with
offices located at 54 Lenox Avenue, Clifton NJ 07014 (“Efrat”),
on the other hand, and Accelerated Pharma, Inc., a Delaware corporation with offices located at 15W155 81st Street,
Burr Ridge, IL 60527 (the “Company”), and relates to certain securities issued by the Company, as set forth in the
Recitals below. Alpha and Brio, each a Purchaser and collectively the “Purchasers, and Firstfire and Efrat, each a Seller
and collectively, the “Sellers.” Firstfire, Efrat, Alpha, Brio and the Company are sometimes referred to individually,
as a “Party” and collectively, as the “Parties.”

 

WHEREAS,
Efrat, a Seller, is the holder and record owner of a Senior Convertible Promissory Note originally issued by Accelerated
Pharma, Inc. to Firstfire in the principal amount of $345,000 dated January 30, 2017 (the “Convertible Note”)
and Firstfire, a Seller is the holder and record owner of 115,000 shares of the Company’s common stock, par value
$0.00001 (the “Shares”), evidenced by a Statement of Account and Total
Holder Account Statement attached hereto, 40,000 of which Shares were issued on January 31, 2017 and 75,000 Shares on June 20,
2017 (the Convertible Note and Shares are sometimes referred to collectively, as the “Securities”); and

 

 WHEREAS, the
Convertible Note issued to Firstfire contained a Confession of Judgment in the event of a default by the Company; and 

 

WHEREAS,
on December 27, 2017, Firstfire sold, transferred and assigned the Convertible Note to Efrat and unless context requires otherwise,
Firstfire and Efrat are sometimes referred to collectively, as the “Sellers;” and

 

WHEREAS,
the Sellers desires to sell, transfer and assign all right, title and interest in the Securities for the total purchase price
of $290,000 (the “Purchase Price”), payable $280,000 to Efrat for the sale of the Convertible Note and $10,000 payable
to Firstfire for the sale of the Shares; and

 

WHEREAS, the
Parties acknowledge that October 22, 2018, the Company filed a registration statement with the United States Securities and Exchange
Commission (the “SEC”) on Form S-1 (the “Registration Statement”) for the purpose of raising gross proceeds
of $3 million from the offering and sale to the public (the “Offering”) of its securities under the Securities Act
of 1933, as amended (the “Act”) and that the subject Offering is being conducted by the Company on a self-underwritten
basis and that no minimum is required to close the Offering; and

 

WHEREAS, each
Purchaser agrees to purchase and accept the transfer and assignment of all right, title and interest in the Securities in the
percentages and amounts as set forth in Section 1(a) below and pay their respective obligations to pay the Purchase Price in the
sums set forth in Section 1(b) below; and

 

 WHEREAS,
the Purchasers hereby agree that upon the closing of this Agreement
(the “Closing”), which Closing is subject to the closing of the Offering, the Purchasers expressly agree that the
Confession of Judgment by waived and be deemed null and void and that following the Closing and the issuance of new Purchaser’s
Notes (as defined in Section 1.a below), no Confession of Judgment provisions will be contained therein; and 

 

WHEREAS,
the Parties acknowledge and agree that the Closing of this Agreement and the transactions contemplated herein are subject
to the closing of the Offering by the Company and that if the closing of the Offering does not occur, then this Agreement shall
become null and void and the obligations of the Parties to each other hereunder shall terminate in their entirety.

 

NOW
THEREFORE, the Purchasers and Sellers, with the agreement and consent of the Company, hereby agree as follows:

 

1.
PURCHASE AND SALE OF Convertible NOTE AND SHARES.

 

a.
Purchase of Convertible Note and Shares. On the Closing Date (as defined below), the Sellers shall sell,
transfer and assign to Alpha and Brio, each a Purchaser, and Alpha and Brio, each a Purchaser, agree to purchase from the Sellers
all right, title and interest in the Securities, evidenced by the Convertible Note and the Shares, for the consideration and
in the form of payment as set forth immediately below and, contemporaneous therewith, the Seller shall deliver instruments of
transfer and assignment of the Securities, including but not limited to stock powers bearing executed medallion guaranties and
such other documents to convey all right, title and interest in the Securities to each Purchaser (the “Transfer Instruments”),
providing for: (i) a total of 89.35% of the Securities being sold, transferred and assigned to Alpha, evidenced by $308,257.50
in principal amount of the Convertible Note, plus accrued interest thereon; and (ii) a total of 10.65% of the Securities being
sold, transferred and assigned to Brio, evidenced by $36,742.50 in principal amount of the Convertible Note, plus accrued interest
thereon, and 115,000 Shares. The two Convertible Notes, in the respective amount of $308,257.50 and $36,742.50, are
sometimes referred to collectively, as the Purchasers’ Notes and individually, as a Purchaser’s Note.

 

b.
Form of Payment. On the Closing Date (as defined below), the Purchasers, separately and not jointly, shall pay the Purchase
Price or $290.000 for the Securities to be transferred and sold to the respective Purchasers at the Closing, as defined below,
with: (i) Alpha paying Efrat 89.35% of the $280,000 attributable to the Purchase Price of the Convertible Note and Brio paying
Efrat 10.65% $280,000 attributable to the Purchase Price of the Convertible Note; and (ii) Alpha paying Firstfire 89.35% of the$10,000
Purchase Price of the Shares and Brio paying Firstfire 10.65% of the $10,000 Purchase Price of the Shares. The total Purchase
Price of $290,000 shall be paid to the Sellers by wire transfer of immediately available funds to the Seller or account designated
by the Seller, in accordance with the written wiring instructions, against delivery of the Securities and Transfer Instruments.

 

    	 

    	 

    

 

c. Agreement
of the Company. The Company, within five (5) business days of execution of this Agreement the Company: (i) will issue a new
Convertible Note in the name of: (a) Alpha or Alpha’s designees, in the principal amount of $308,257.50 plus accrued interest;
and (b) Brio or Brio’s designees, in the principal amount of $36,742.50 plus accrued interest (each, a, “Purchaser’s
Notes” and collectively, the “Purchasers’ Notes”); and (ii) will cause its transfer agent to issue in
book entry form certificates evidencing: (c) 102,752.5 Shares in the name of Alpha or Alpha’s designees; and (d) 12,247.5
Shares in the name of Brio or Brio’s designees (the “Purchaser’s Shares” and, collectively, the “Purchasers’
Shares”). The Purchasers’ Notes shall contain such terms and conditions as the Purchasers, collectively, shall direct
in writing. In the alternative, the Company and the Purchasers, acting singly and not collectively, can authorize the Company
to issue and deliver such other securities of the Company as the respective Purchasers shall determine (the “Purchasers’
Securities”). The Purchasers’ Notes, Purchasers’ Shares and/or Purchaser Securities may be referred to hereinafter
as the “Securities.”

 

d. Closing
Date. Subject to the satisfaction (or written waiver) of the conditions thereto set forth below, the date and time of the
issuance and sale of the Securities pursuant to this Agreement (the “Closing Date”) shall be 12:00 noon, Eastern Standard
Time not later than three (3) business days after the closing of the Offering, or such other mutually agreed upon time.
The closing of the transactions contemplated by this Agreement (the “Closing”) shall occur on the Closing Date at
such location as may be agreed to by the Parties.

 

2.
REPRESENTATIONS AND WARRANTIES OF THE SELLERS. The Sellers represent and warrant to the Purchasers and
the Company that:

 

a.
Ability to Carry Out Obligations. Each Seller has the right, power, and authority to enter into this Agreement and
to bind each Seller to the representations and warranties hereof and perform each Seller’s obligations under
this Agreement. The execution and delivery of this Agreement by each of the Sellers and the performance by each
of the Sellers of its obligations hereunder will not cause, constitute, or conflict with or result in (i) any breach
or violation or any of the provisions of or constitute a default under any license, indenture, mortgage, charter, instrument,
articles of incorporation, bylaw, or other agreement or instrument to which either Seller is a party, or by which
either Seller may be bound, nor will any consents or authorizations of any party other than those hereto be required, (ii)
an event that would cause either Seller to be liable to any third-party, or (iii) an event that would result in the creation
or imposition of any lien, charge, or encumbrance on any of the Securities being acquired by the Purchasers pursuant
to this Agreement. In addition, each Seller represents and warrants that no person holds power of attorney or other
interest whatsoever that could adversely affect the ability of either Seller to transfer all right, title and interest
in each Seller’s Securities to the Purchasers under this Agreement.

 

b.
Title. Each Seller has good and marketable title to each Seller’s respective Securities evidenced
by the Convertible Note in the name of Efrat, in the form attached hereto as Exhibit A, and the Shares in the
name of Firstfire, evidenced by a Statement of Account attached hereto as Exhibit B (collectively,
the “Securities”) being sold, transferred and assigned to the Purchasers pursuant to this Agreement.
The Securities will be, at the Closing, free and clear of all liens, security interests, pledges, charges, claims, encumbrances
and restrictions of any kind, including but not limited to any restrictions on transfer imposed by federal and state securities
laws. Neither Efrat’s Convertible Note nor Firstfire’s Shares are or will be subject to any voting trust or
agreement with any third party. No person holds or has the right to receive any proxy or similar instrument with respect to each
Seller’s Securities. Except as provided in this Agreement, neither Seller is a party to any agreement
which offers or grants to any person, other than the Purchasers, the right to purchase or acquire any of the Securities.
There is no applicable local, state or federal law, rule, regulation, or decree which would, as a result of the purchase of the
Securities by the Purchasers (and/or assigns) impair, restrict or delay voting or any other ownership rights with
respect to the Securities by the Purchasers.

 

    	2

    	 

    

 

c.
Transfer of Shares. Firstfire, as a Seller of the Shares, within five (5) business days of execution of this
Agreement, will deliver the book entry statement(s), along with irrevocable stock powers bearing
medallion guarantees and/or an Officer’s Certificate and Letter of Instructions to VStock Transfer (the “Transfer
Agent”) so as to permit the Transfer Agent, in a timely manner, to issue the Shares in the names of the Purchasers
or Purchasers’ designees.

 

3. REPRESENTATIONS
AND WARRANTIES OF THE PURCHASERS. The Purchasers represent and warrant, individually and not collectively, to the Sellers
and the Company, that:

 

a.
Investment Purpose. Each Purchaser, as of the date of this Agreement, is purchasing the Securities from the Sellers
and/or is being issued the Securities by the Company for its own account or for the account of its designees and not with
a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration
under the Securities Act of 1933, as amended (the “Act”) and the rules and regulations promulgated by the United States
Securities and Exchange Commission (the “SEC”) under the Act; provided, however, that by making the
representations herein, each Purchaser understands that it is not agreeing to hold any of the Securities for any minimum or other
specific term and reserves the right to dispose of their Purchaser’s Securities at any time in accordance with or pursuant
to a registration statement or an exemption under the Act and the rules and regulations of the SEC under the Act.

 

b. Accredited
Investor Status. Each Purchaser is an “accredited investor” as that term is defined in Rule 501(a) of Regulation
D (an “Accredited Investor”).

 

c. Reliance
on Exemptions. Each Purchaser understands that the Securities are being acquired, transferred and assigned to each Purchaser
in reliance upon specific exemptions from the registration requirements of the Act and the rules and regulations of the SEC under
the Act and any applicable state securities laws and that the Company and Seller is relying upon the truth and accuracy of, and
each respective Purchaser’s compliance with, the representations, warranties, agreements, acknowledgments and understandings
of each Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of each Purchaser
to acquire the Securities.

 

    	3

    	 

    

 

d. Information.
Each Purchaser and its advisors, if any, have been, and for so long as the Securities remain outstanding will continue to be,
furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer
and sale of other securities of the Company which have been reasonably requested by each Purchaser and/or their respective advisors.
Each Purchaser and/or their respective advisors, if any, have been, and for so long as the Securities remain outstanding will
continue to be, afforded the opportunity to ask questions of the Company. Notwithstanding the foregoing, the Company has not disclosed
to either Purchaser any material nonpublic information and will not disclose such information unless such information is disclosed
to the public prior to or promptly following such disclosure to such Purchaser(s). Neither inquiries nor any other due diligence
investigation conducted by either Purchaser or any of their respective advisors or representatives shall modify, amend or affect
either Purchaser’s right to rely on the Company’s representations and warranties contained in Section 3 below. Each
Purchaser understands that its investment in the Securities involves a significant degree of risk. Neither Purchaser is aware
of any facts that may constitute a breach of any of the Company’s representations and warranties made herein.

 

e. Governmental
Review. Each Purchaser understands that no United States federal or state agency or any other government or governmental agency
has passed upon or made any recommendation or endorsement of the Securities.

 

f. Transfer
or Re-sale. Each Purchaser understands that (i) the sale, transfer and assignment of the Securities to the Purchasers has
not been and is not being registered under the Act or any applicable state securities laws, and the Securities issued to the Purchaser
or its designees may not be sold, transferred and/or assigned unless (a) the Securities are sold pursuant to an effective registration
statement under the Act, (b) each Purchaser shall have received from the Company, at the cost of the Company, an opinion of counsel
that that the Company undertakes to provide in a timely manner and shall be in form, substance and scope customary for opinions
of counsel in comparable transactions to the effect that the Securities to be sold or transferred may be sold or transferred pursuant
to an exemption from such registration, which opinion shall be accepted by the Company, (c) the Securities are sold or transferred
to an “affiliate” (as defined in Rule 144 promulgated under the Act (or a successor rule) (“Rule 144”)
of the requesting Purchaser who agrees to sell or otherwise transfer the Securities only in accordance with this Section 3.f and
who is an Accredited Investor, (d) the Securities are being issued in reliance upon Section 4(2) of the Act or pursuant to Rule
144 promulgated by the SEC under the Act, or (e) the Securities are being issued in reliance upon Section 4(2) or pursuant to
Rule 144 promulgated by the SEC under the Act (or a successor rule) and the requesting Purchaser shall have delivered to the Company,
at the cost of the Company, an opinion of counsel that shall be in form, substance and scope customary for opinions of counsel
in corporate transactions, which opinion shall be accepted by the Company; (ii) any sale of such Securities made in reliance on
Rule 144 may be made only in accordance with the terms of said Rule 144 and further, if said Rule 144 is not applicable, any re-sale
of such Securities under circumstances in which the seller (or the person through whom the sale is made) may be deemed to be an
underwriter (as that term is defined in the Act) may require compliance with some other exemption under the Act or the rules and
regulations of the SEC thereunder; and (iii) neither the Company nor any other person is under any obligation to register such
Securities under the Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder (in
each case). Notwithstanding the foregoing or anything else contained herein to the contrary, the Securities may be pledged as
collateral in connection with a bona fide margin account or other lending arrangement.

 

    	4

    	 

    

 

e. Legends.
Each Purchaser understands that until such time as the Securities may be sold, either pursuant to an effective registration statement
under the Act or pursuant to Rule 144 without any restriction as to the number of securities as of a particular date that can
then be immediately sold, the Securities and any Shares being acquired upon conversion of any Securities may bear a restrictive
legend in substantially the following form (and a stop-transfer order may be placed against transfer of the certificates for such
Securities):

 

“NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT
BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN
A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE
144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT
OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.”

 

The
legend set forth above shall be removed and the Company shall issue one or more certificates without such legend to the new holder
of any Security upon which it is stamped, if, unless otherwise required by applicable state securities laws, (a) such Security
is registered for sale under an effective registration statement filed under the Act or otherwise may be sold pursuant to Rule
144 without any restriction as to the number of securities as of a particular date that can then be immediately sold, or (b) such
holder provides the Company with an opinion of counsel, in form, substance and scope customary for opinions of counsel in comparable
transactions, to the effect that a public sale or transfer of such Security may be made without registration under the Act, which
opinion shall be accepted by the Company so that the sale or transfer is effected. Each Purchaser agrees to sell all Securities,
including those represented by a certificate(s) from which the legend has been removed, in compliance with applicable prospectus
delivery requirements, if any.

 

f. Authorization;
Enforcement. This Agreement has been duly and validly authorized. This Agreement has been duly executed and delivered on behalf
of each Purchaser, and this Agreement constitutes a valid and binding agreement of each Purchaser enforceable in accordance with
its terms.

 

g.
Limitation on Acquisition of Shares. The Parties agree that in no event may either Purchaser convert the Convertible Note
or exercise any of the Securities if, as a result of any such conversion or exercise, such Purchaser shall be the beneficial owner
of more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of shares of Common Stock issuable upon conversion of the Convertible Note or the exercise of any Securities containing rights
to acquire or be exchanged for shares of Common Stock (the “Beneficial Ownership Limitation”). Each Purchaser may
decrease the Beneficial Ownership Limitation at any time and each Purchaser, upon not less than 61 days’ prior notice to
the Company, may increase the Beneficial Ownership Limitation under this Section 3.g, provided that the Beneficial Ownership Limitation
in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of shares of Common Stock upon conversion of the Convertible Note or the exercise of any Securities containing rights to acquire
or be exchanged for shares of Common Stock held by such Purchaser and the Beneficial Ownership Limitation provisions of this Section
3.g shall continue to apply. Any such increase will not be effective until the 61st day after such notice is delivered
to Company. The Beneficial Ownership Limitation provisions of this paragraph shall be construed and implemented in a manner otherwise
than in strict conformity with the terms of this Section 3.g to correct this paragraph (or any portion hereof) which may be defective
or inconsistent with the intended Beneficial Ownership Limitation contained herein or to make changes or supplements necessary
or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor
holder of the Convertible Note or any Securities.

 

    	5

    	 

    

 

4.
REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company represents and warrants to the Purchasers that:

 

a.
Organization and Qualification. The Company and each of its Subsidiaries (as defined below), if any, is a corporation duly
organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, with full power
and authority (corporate and other) to own, lease, use and operate its properties and to carry on its business as and where now
owned, leased, used, operated and conducted. The Company and each of its Subsidiaries is duly qualified as a foreign corporation
to do business and is in good standing in every jurisdiction in which its ownership or use of property or the nature of the business
conducted by it makes such qualification necessary except where the failure to be so qualified or in good standing would not have
a Material Adverse Effect. “Material Adverse Effect” means any material adverse effect on the business, operations,
assets, financial condition or prospects of the Company or its Subsidiaries, if any, taken as a whole, or on the transactions
contemplated hereby or by the agreements or instruments to be entered into in connection herewith. “Subsidiaries”
means any corporation or other organization, whether incorporated or unincorporated, in which the Company owns, directly or indirectly,
any equity or other ownership interest.

 

b.
Authorization; Enforcement. (i) The Company has all requisite corporate power and authority to enter into and perform this
Agreement and to consummate the transactions contemplated hereby and thereby and to issue the Securities, if any, in accordance
with the terms hereof and thereof, (ii) the execution and delivery of this Agreement, the Purchasers’ Securities by the
Company and the consummation by it of the transactions contemplated hereby and thereby (including without limitation, the issuance
of the Purchasers notes and the issuance and reservation for issuance of the Shares issuable upon conversion or exercise thereof)
have been duly authorized by the Company’s Board of Directors and no further consent or authorization of the Company, its
Board of Directors, or its shareholders is required, (iii) this Agreement has been duly executed and delivered by the Company
by its authorized representative, and such authorized representative is the true and official representative with authority to
sign this Agreement and the other documents executed in connection herewith and bind the Company accordingly, and (iv) this Agreement
constitutes, and upon execution and delivery by the Company of the Purchasers’ Notes, each of such instruments will constitute,
a legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms.

 

c. Capitalization.
As of the date hereof, the authorized capital stock of the Company consists of: (i) 45,000,000 shares of Common Stock, par value
$0.00001 per share (the “Common Stock”); and (ii) 5,000,000 shares of preferred stock, par value $0.00001 per share
(the “Preferred Stock”). As of the date of this Agreement, the Company has 6,220,190 shares of Common Stock issued
and outstanding and 180,000 shares of Series A Preferred Stock issued and outstanding. The Company’s Board of Directors
is empowered, without stockholder approval, to issue Preferred Stock with dividend, liquidation, redemption, voting or other rights
which could adversely affect the voting power or other rights of the holders of Common Stock. All of the issued and outstanding
shares of Common Stock and Preferred Stock are validly issued, fully paid and non-assessable. No shares of Common Stock or Preferred
Stock of the Company are subject to preemptive rights or any other similar rights of the shareholders of the Company or any liens
or encumbrances imposed through the actions or failure to act of the Company. Except as disclosed in the Company’s pending
registration statement on Form S-1 filed with the SEC on October 22, 2018 (the “Registration Statement”) or as otherwise
set forth in this Agreement, (i) there are no outstanding options, warrants, scrip, rights to subscribe for, puts, calls, rights
of first refusal, agreements, understandings, claims or other commitments or rights of any character whatsoever relating to, or
securities or rights convertible into or exchangeable for any shares of capital stock of the Company or any of its Subsidiaries,
or arrangements by which the Company or any of its Subsidiaries is or may become bound to issue additional shares of capital stock
of the Company or any of its Subsidiaries, (ii) there are no agreements or arrangements under which the Company or any of its
Subsidiaries is obligated to register the sale of any of its or their securities under the Act and (iii) there are no anti-dilution
or price adjustment provisions contained in any security issued by the Company (or in any agreement providing rights to security
holders) that will be triggered by the issuance of the Note or the Conversion Shares. The Company has filed with the SEC in its
Registration Statement or in registration statements filed under the Act and amendments thereto during the period from October
11, 2016 through July 12, 2017, which registration statement and amendments were withdrawn on August 23, 2017 (collectively, the
“SEC Documents”), true and correct copies of the Company’s Certificate of Incorporation as in effect on the
date hereof and thereof (the “Certificate of Incorporation”), the Company’s By-laws, as in effect on the date
hereof (the “By-laws”), and the terms of all securities convertible into or exercisable for Common Stock of the Company
and the material rights of the holders thereof in respect thereto. The Company shall provide the Purchaser with a written update
of this representation signed by the Company’s Chief Executive on behalf of the Company as of the Closing Date.

 

    	6

    	 

    

 

d. Issuance
of Securities. The issuance and/or transfer to the Purchasers of the Purchasers’ Notes and Securities, if any, when
issued, will be duly authorized and, upon issuance in accordance with the terms of this Agreement, will be validly issued, fully
paid and non-assessable and free from all preemptive or similar rights, taxes, liens, charges and other encumbrances with respect
to the issue thereof. Any shares of Common Stock underlying conversion of the Purchasers’ Notes are duly authorized and
reserved for issuance and, upon conversion, if any, of the Purchasers’ Notes in accordance with its terms, or the issuance
of Securities in either full or partial exchange for the Purchasers’ Notes will be validly issued, fully paid and non-assessable,
and free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive
rights or other similar rights of shareholders of the Company and will not impose personal liability upon the holder thereof.

 

e. Acknowledgment
of Dilution. The Company understands and acknowledges the potentially dilutive effect to the Common Stock upon the issuance
of shares of Common Stock upon conversion of and underlying the Purchasers’ Notes and the conversion, if any, of the Purchasers’
Securities in accordance with this Agreement is absolute and unconditional regardless of the dilutive effect that such issuance
may have on the ownership interests of other shareholders of the Company.

 

f. No
Conflicts. The execution, delivery and performance of this Agreement and the consummation by the Company of the transactions
contemplated hereby and thereby (including, without limitation, the issuance any Securities and reservation for issuance of the
shares of Common Stock underlying the Purchasers’ Notes or any amendment thereto) will not (i) conflict with or result in
a violation of any provision of the Certificate of Incorporation or By-laws, or (ii) violate or conflict with, or result in a
breach of any provision of, or constitute a default (or an event which with notice or lapse of time or both could become a default)
under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture, patent,
patent license or instrument to which the Company or any of its Subsidiaries is a party, or (iii) result in a violation of any
law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and regulations
of any self-regulatory organizations to which the Company or its securities are subject) applicable to the Company or any of its
Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected (except for such
conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would not, individually or in the
aggregate, have a Material Adverse Effect). Neither the Company nor any of its Subsidiaries is in violation of its Certificate
of Incorporation, By-laws or other organizational documents and neither the Company nor any of its Subsidiaries is in default
(and no event has occurred which with notice or lapse of time or both could put the Company or any of its Subsidiaries in default)
under, and neither the Company nor any of its Subsidiaries has taken any action or failed to take any action that would give to
others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which
the Company or any of its Subsidiaries is a party or by which any property or assets of the Company or any of its Subsidiaries
is bound or affected, except for possible defaults as would not, individually or in the aggregate, have a Material Adverse Effect.
The businesses of the Company and its Subsidiaries, if any, are not being conducted, and shall not be conducted so long as the
Purchaser owns any of the Securities, in violation of any law, ordinance or regulation of any governmental entity. Except as specifically
contemplated by this Agreement and as required under the Act and any applicable state securities laws, the Company is not required
to obtain any consent, authorization or order of, or make any filing or registration with, any court, governmental agency, regulatory
agency, self-regulatory organization or stock market or any third party in order for it to execute, deliver or perform any of
its obligations under this Agreement or the transactions contemplated hereby in accordance with the terms hereof. All consents,
authorizations, orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence have
been obtained or effected on or prior to the date hereof.

 

    	7

    	 

    

 

g. Absence
of Certain Changes. Since October 22, 2018, the date of the filing of the Registration Statement with the SEC, there has been
no material adverse change and no material adverse development in the assets, liabilities, business, properties, operations, financial
condition, results of operations, prospects or status of the Company or any of its Subsidiaries.

 

h. Absence
of Litigation. There is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public board,
government agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its Subsidiaries,
threatened against or affecting the Company or any of its Subsidiaries, or their officers or directors in their capacity as such,
that could have a Material Adverse Effect.

 

i. Patents,
Copyrights, etc. The Company and each of its Subsidiaries owns or possesses the requisite licenses or rights to use all patents,
patent applications, patent rights, inventions, know-how, trade secrets, trademarks, trademark applications, service marks, service
names, trade names and copyrights (“Intellectual Property”) necessary to enable it to conduct its business as now
operated (and, as presently contemplated to be operated in the future). Except as disclosed in the SEC Documents, there is no
claim or action by any person pertaining to, or proceeding pending, or to the Company’s knowledge threatened, which challenges
the right of the Company or of a Subsidiary with respect to any Intellectual Property necessary to enable it to conduct its business
as now operated (and, as presently contemplated to be operated in the future); to the best of the Company’s knowledge, the
Company’s or its Subsidiaries’ current and intended products, services and processes do not infringe on any Intellectual
Property or other rights held by any person; and the Company is unaware of any facts or circumstances which might give rise to
any of the foregoing. The Company and each of its Subsidiaries have taken reasonable security measures to protect the secrecy,
confidentiality and value of their Intellectual Property.

 

j. No
Materially Adverse Contracts, Etc. Neither the Company nor any of its Subsidiaries is subject to any charter, corporate or
other legal restriction, or any judgment, decree, order, rule or regulation which in the judgment of the Company’s officers
has or is expected in the future to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is a party
to any contract or agreement which in the judgment of the Company’s officers has or is expected to have a Material Adverse
Effect.

 

k. Certain
Transactions. Except for arm’s-length transactions pursuant to which the Company or any of its Subsidiaries makes payments
in the ordinary course of business upon terms no less favorable than the Company or any of its Subsidiaries could obtain from
third parties and other than the grant of stock options disclosed in the Registration Statement, none of the officers, directors,
or employees of the Company is presently a party to any transaction with the Company or any of its Subsidiaries (other than for
services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing
of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from
any officer, director or such employee or, to the knowledge of the Company, any corporation, partnership, trust or other entity
in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner.

 

l. Acknowledgment
Regarding Purchasers’ Acquisition of the Securities. The Company acknowledges and agrees that each Purchaser is acting
on its own behalf, solely in the capacity of an arm’s-length purchaser with respect to this Agreement and the transactions
contemplated hereby, including but not limited to each Purchaser’s acquisition of all right, title and interest in the Convertible
Notes and the Shares in book entry form from the respective Sellers. The Company further acknowledges that neither
Purchaser is acting nor has acted as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect
to this Agreement and the transactions contemplated hereby and any statement made by either Purchaser or any of their respective
representatives or agents in connection with this Agreement and the transactions contemplated hereby is not advice or a recommendation
and is merely incidental to each Purchaser’s purchase and/or acquisition of the Securities from the Sellers. The
Company further represents to the Purchasers and the Sellers that the Company’s consent to the execution and delivery
of this Agreement has been based solely on the independent evaluation of the Company and its representatives.

 

    	8

    	 

    

 

m. No
Brokers. The Company has taken no action which would give rise to any claim by any person for brokerage commissions, transaction
fees or similar payments relating to this Agreement or the transactions contemplated hereby.

 

n. Title
to Property. Except as disclosed in the SEC Documents, the Company and its Subsidiaries have good and marketable title in
fee simple to all real property and good and marketable title to all personal property owned by them which is material to the
business of the Company and its Subsidiaries, in each case free and clear of all liens, encumbrances and defects or such as would
not have a Material Adverse Effect. Any real property and facilities held under lease by the Company and its Subsidiaries are
held by them under valid, subsisting and enforceable leases with such exceptions as would not have a Material Adverse Effect.

 

o. Shell
Status. The Company represents that it is not a “shell” issuer and has never been a “shell” issuer,
or that if it previously has been a “shell” issuer, that at least twelve (12) months have passed since the Company
has reported Form 10 type information indicating that it is no longer a “shell” issuer. Further, the Company will
instruct its counsel to either (i) write a 144-3(a)(9) opinion to allow for salability of any Shares issued on conversion of the
Convertible Note or other Securities convertible into Shares, or (ii) accept such opinion from counsel to the Purchaser(s).

 

p. Corporate
Existence. So long as either Purchaser beneficially owns all or any portion of the Purchasers’ Notes, the Purchasers’
Shares or the Securities or any portion thereof, acquired under this Agreement, the Company shall maintain its corporate existence
and shall not sell all or substantially all of the Company’s assets, except in the event of a merger or consolidation or
sale of all or substantially all of the Company’s assets, where the surviving or successor entity in such transaction assumes
the Company’s obligations hereunder and under the agreements and instruments entered into in connection herewith.

 

q. Restriction
on Activities. Commencing as of the date first above written, and until the later of the six month anniversary of the date
first written above or payment or conversion of the Purchasers’ Notes in full, or the issuance of Securities in exchange
for the Purchasers’ Notes, the Company shall not, directly or indirectly, without each Purchaser’s prior written consent,
which consent shall not be unreasonably withheld: (a) change the nature of its business; (b) sell, divest, acquire, change the
structure of any material assets other than in the ordinary course of business; or (c) solicit any offers for, respond to any
unsolicited offers for, or conduct any negotiations with any other person or entity in respect of any variable rate debt transactions
(i.e., transactions were the conversion or exercise price of the security issued by the Company varies based on the market price
of the Common Stock) above $500,000, whether a transaction similar to the one contemplated hereby or any other investment; or
(d) file any registration statements with the SEC.

 

w. Legal
Counsel Opinions. Upon the request of either Purchaser, from to time to time, the Company shall be responsible (at its cost)
for promptly supplying to the Company’s Transfer Agent and each requesting Purchaser a customary legal opinion letter of
its counsel (the “Legal Counsel Opinion”) to the effect that the sale of any shares of Common Stock underlying conversion
of the Purchasers’ Notes or other Securities issuable upon exchange of the Purchasers’ Notes or other Securities by
the Purchaser or its affiliates, successors and assigns is exempt from the registration requirements of the Act pursuant to Rule
144 (provided the requirements of Rule 144 are satisfied and provided the such shares of Common Stock are not then registered
under the Act for resale pursuant to an effective registration statement). Should the Company’s legal counsel fail for any
reason to issue the Legal Counsel Opinion, either Purchaser may (at the Company’s cost) secure another legal counsel to
issue the Legal Counsel Opinion, and the Company will instruct its transfer agent to accept such opinion. If the Company previously
has been a “shell” issuer, the legal Counsel Opinion shall state that at least twelve (12) months have passed since
the Company has reported Form 10 type information indicating that it is no longer a “shell” issuer. Further, the Company
will instruct its counsel to either (i) write a 144-3(a)(9) opinion to allow for salability of any Shares issued on conversion
of the Purchasers’ Notes or other Securities convertible into Shares, or (ii) accept such opinion from each Purchaser’s
counsel.

 

    	9

    	 

    

 

y. Breach
of Covenants. The Company agrees that if the Company breaches any of the representations, warranties or covenants set forth
in this Section 4, and in addition to any other remedies available to each Purchaser pursuant to this Agreement, it will be considered
an Event of Default, as that term is defined in the Convertible Note issued to Firstfire on January 30, 2017, the Company
shall pay to the Purchasers the Standard Liquidated Damages Amount, as defined in said Convertible Note, in cash or in
shares of Common Stock at the option of the Purchasers, until such breach is cured, or the Company shall pay to the Purchasers
the Standard Liquidated Damages Amount in cash or shares of Common Stock, at the option of the Purchasers, upon each
violation of such provision. If the Company elects to pay the Standard Liquidated Damages Amounts in shares of Common Stock, such
shares shall be issued at the Conversion Price at the time of payment.

 

z. Rule
144. The Company acknowledges and agrees that in accordance with Rule 144, the holding period of the Securities will tack
back to the date such Securities sold and transferred therefor were initially issued. The Company agrees not to take a position
to the contrary.

 

5. CONDITIONS
PRECEDENT TO THE OBLIGATIONS OF THE SELLERS, PURCHASERS AND COMPANY. The obligation of the Sellers, Purchasers
and the Company hereunder to: (i) issue and sell the Purchasers’ Notes and Shares by the Sellers to the Purchasers
at the Closing; and (ii) the issuance by the Company of Securities to the Purchasers in exchange for the Purchasers’ Notes
and/or the Shares or a portion thereof is subject to the satisfaction, at or before the Closing Date of each of the following
conditions thereto, provided that these conditions are for the sole benefit and may be waived by the Sellers, Purchasers
and/or the Company, as the case may be, at any time in their sole discretion:

 

a. The
Parties shall have executed this Agreement and delivered the same together with all certificates and other instruments contemplated
hereby.

 

b. The
Purchasers shall have delivered their respective portions of the Purchase Price in accordance with Section 1.b above.

 

c. The
representations and warranties of each Purchaser and the Company shall be true and correct in all material respects as
of the date when made and as of the Closing Date as though made at that time (except for representations and warranties that speak
as of a specific date), and the Purchasers shall have performed, satisfied and complied in all material respects with the
covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Purchasers
at or prior to the Closing Date.

 

d. No
litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having
authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this
Agreement.

 

6. CONDITIONS
PRECEDENT TO THE PURCHASERS’ OBLIGATIONS TO PURCHASE. The obligations of each Purchaser hereunder to purchase the Securities
at the Closing is subject to the satisfaction, at or before the Closing Date of each of the following conditions, provided that
these conditions are for each Purchaser’s sole benefit and may be waived by each Purchaser at any time in its sole discretion,
with it being understood that any such waiver will only be applicable to the waiving Purchaser:

 

a. The
Company and Sellers shall have executed this Agreement and delivered the same to the Purchasers.

 

b. The
Company shall have delivered to the Purchasers the duly executed Purchasers’ Notes (in such denominations as each
Purchaser shall request) and in accordance with Section 1.b above.

 

c. The
Irrevocable Transfer Agent Instructions, in form attached hereto, shall have been delivered to and acknowledged in writing by
the Company’s Transfer Agent.

 

d. The
representations and warranties of the Company shall be true and correct in all material respects as of the date when made and
as of the Closing Date as though made at such time (except for representations and warranties that speak as of a specific date)
and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions
required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date. Each Purchaser
shall have received a certificate or certificates, executed by the chief executive officer of the Company, dated as of the Closing
Date, to the foregoing effect and as to such other matters as may be reasonably requested by each Purchaser including, but not
limited to certificates with respect to the Company’s Certificate of Incorporation, By-laws and Board of Directors’
resolutions relating to the transactions contemplated hereby.

 

    	10

    	 

    

 

e. No
litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having
authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this
Agreement.

 

f. No
event shall have occurred which could reasonably be expected to have a Material Adverse Effect on the Company.

 

g. Each
Purchaser shall have received an officer’s certificate described in Section 3.c above, dated as of the Closing Date.

 

7. GOVERNING
LAW; MISCELLANEOUS.

 

a. Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard
to principles of conflicts of laws. Any action brought by any Party against the other Parties concerning the transactions contemplated
by this Agreement, the Securities or any other agreement, certificate, instrument or document contemplated hereby shall be brought
only in the state courts of the State of New York or in the federal courts located in the State of New York, County of New York.
The Parties to this Agreement hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder
and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. EACH PARTY
HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE
HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT, ANY OTHER TRANSACTION
DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY. The prevailing Party shall be entitled to recover from the other
Party its reasonable attorney’s fees and costs. In the event that any provision of this Agreement or any other agreement delivered
in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed
inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of
law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability
of any other provision of any agreement. Each Party hereby irrevocably waives personal service of process and consents to process
being served in any suit, action or proceeding in connection with this Agreement by mailing a copy thereof via registered or certified
mail or overnight delivery (with evidence of delivery) to such Party at the address in effect for notices to it under this Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

 

b. Counterparts;
Signatures by Facsimile. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original
but all of which shall constitute one and the same agreement and shall become effective when counterparts have been signed by
each party and delivered to the other Party. This Agreement, once executed by a Party, may be delivered to the other party hereto
by facsimile transmission of a copy of this Agreement bearing the signature of the Party so delivering this Agreement.

 

c. Construction;
Headings. This Agreement shall be deemed to be jointly drafted by the Company and the Purchasers and shall not be construed
against any person as the drafter hereof. The headings of this Agreement are for convenience of reference only and shall not form
part of, or affect the interpretation of, this Agreement.

 

d. Severability.
In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then
such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform
with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect
the validity or enforceability of any other provision hereof.

 

    	11

    	 

    

 

e. Entire
Agreement; Amendments. This Agreement, the Securities and the instruments referenced herein contain the entire understanding
of the Parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein,
neither the Company nor either Purchaser makes any representation, warranty, covenant or undertaking with respect to such matters.
No provision of this Agreement may be waived or amended other than by an instrument in writing signed by the majority in interest
of the respective Purchasers.

 

f. Notices.
All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing
and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return
receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted
by hand delivery, telegram, email, or facsimile, addressed as set forth below or to such other address as such party shall have
specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall
be deemed effective (a) upon hand delivery or delivery by email or facsimile, with accurate confirmation generated by the transmitting
facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where
such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during
normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by
express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first
occur. The addresses for such communications shall be as first set forth above. With a copy to (which copy shall not constitute
notice):

 

If
to Purchasers’ Counsel, then to:

 

Barbara
Mittman, Esq.

Grushko
& Mittman, P.C.

515
Rockaway Avenue

Valley
Stream, New York 11581

Email:
counslers@aol.com

 

If
to Sellers’ Counsel, then to:

 

Chad
Friend, Esq.

Legal
& Compliance, LLC

330
Clematis Street, Suite 217

West
Palm Beach, FL 33401

Email:
cfriend@legalandcompliance.com

 

If
to the Company’s Counsel, then to:

 

Lawrence
R. Lonergan, Esq.

The
Lonergan Law Firm, LLC

96
Park Street

Montclair,
NJ 07042

Email:
llonergan@wlesq.com

 

Each
Party shall provide notice to the other Parties of any change in address.

 

    	12

    	 

    

 

g. Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the Parties and their successors and assigns.
Neither the Company, the Sellers nor the Purchasers shall assign this Agreement or any rights or obligations hereunder
without the prior written consent of the other Parties. Notwithstanding the foregoing, the Purchasers may assign their respective
rights hereunder to any person that purchases Securities in a private transaction from either Purchaser or to any of their “affiliates,”
as that term is defined under the Securities Exchange Act of 1934, without the consent of the Company.

 

h. Third-Party
Beneficiaries. This Agreement is intended for the benefit of the Parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

i. Survival.
The representations and warranties of the Parties and the agreements and covenants set forth in this Agreement shall survive the
Closing hereunder not withstanding any due diligence investigation conducted by or on behalf of the Parties. Each Party agrees
to indemnify and hold harmless the other Parties and all their officers, directors, employees and agents for loss or damage arising
as a result of or related to any breach or alleged breach by any Party of any of its representations, warranties and covenants
set forth in this Agreement or any of its covenants and obligations under this Agreement, including advancement of expenses as
they are incurred.

 

j. Further
Assurances. Each Party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

k. No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

 

l. Remedies.
The Parties acknowledge that a breach by any of them of their respective obligations hereunder will cause irreparable harm to
the other Parties by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Parties acknowledge
that the remedy at law for a breach of their obligations under this Agreement will be inadequate and agrees, in the event of a
breach or threatened breach by a Party of the provisions of this Agreement, that the other Parties shall be entitled, in addition
to all other available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions
restraining, preventing or curing any breach of this Agreement and to enforce specifically the terms and provisions hereof, without
the necessity of showing economic loss and without any bond or other security being required.

 

    	13

    	 

    

 

m. Indemnification.
In consideration of each Party’s execution and delivery of this Agreement and sale, transfer and assignment of the Securities
and any Securities hereunder, and in addition to all of the other obligations under this Agreement or the Securities, the Seller
and the Company shall defend, protect, indemnify and hold harmless the Purchaser and its stockholders, partners, members, officers,
directors, employees and direct or indirect investors and any of the foregoing persons’ agents or other representatives
(including, without limitation, those retained in connection with the transactions contemplated by this Agreement) (collectively,
the “Indemnitees”) from and against any and all actions, causes of action, suits, claims, losses, costs, penalties,
fees, liabilities and damages, and expenses in connection therewith (irrespective of whether any such Indemnitee is a party to
the action for which indemnification hereunder is sought), and including reasonable attorneys’ fees and disbursements (the
“Indemnified Liabilities”), incurred by any Indemnitee as a result of, or arising out of, or relating to (a) any misrepresentation
or breach of any representation or warranty made by the Company, and the Seller in this Agreement or the Securities or any other
agreement, certificate, instrument or document contemplated hereby or thereby, (b) any breach of any covenant, agreement or obligation
of the Company and Seller contained in this Agreement or the Securities or any other agreement, certificate, instrument or document
contemplated hereby or thereby or (c) any cause of action, suit or claim brought or made against such Indemnitee by a third party
and arising out of or resulting from (i) the execution, delivery, performance or enforcement of this Agreement or the Securities
or any other agreement, certificate, instrument or document contemplated hereby or thereby, (ii) any transaction financed or to
be financed in whole or in part, directly or indirectly, with the proceeds of the issuance of the Securities, or (iii) the status
of the Purchaser or holder of the Securities as an investor in the Company pursuant to the transactions contemplated by this Agreement.
To the extent that the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make the maximum
contribution to the payment and satisfaction of each of the Indemnified Liabilities that is permissible under applicable law.

 

n. General
Releases. The Parties agree that as a condition to entering into this Agreement, Seller has executed and delivered separate
General Releases to and in favor of each Purchaser and the Company, in the form attached hereto as General Release I and General
Release II and made a part hereof.

 

[signature
page follows]

 

    	14

    	 

    

 

IN
WITNESS WHEREOF, the undersigned Purchaser, Seller and the Company have caused this Agreement to be duly executed as of the date
first above written.

 

	ALPHA
    CAPITAL ANSTALT [PURCHASER]
	 
	/s/:
    Konrad Ackermann	 
	Name:	Konrad
    Ackermann	 
	Title:	Director	 
	 	 	 
	BRIO
    CAPITAL MASTER FUND LTD [PURCHASER]
	 	 	 
	/s/: Shaye Hirsch	 
	Name:	Shaye
    Hirsch	 
	Title:	Managing
    Member	 
	 	 	 
	FIRSTFIRE
    GLOBAL OPPORTUNITIES FUND, LL [SELLER]
	 
	/s/: Eli Fireman	 
	Name: 	Eli
    Fireman	 
	Title:	Managing
    Member	 
	 	 	 
	EFRAT
    INVESTMENTS, LLC [SELLER]
	 	 	 
	/s/: Joel Rotter	 
	Name:	Joel
    Rotter	 
	Title:	Managing
    Member	 
	 	 	 
	ACCELERATED
    PHARMA, INC.
	 	 	 
	/s/: Michael Fonstein	 
	Name:	Michael
    Fonstein	 
	Title:	Chief
    Executive Officer	 

 

    	15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]